As Insulet (Nasdaq:PODD) continues to grow in its leadership position within the insulin patch pump market, other entries ...
Insulet Corporation (NASDAQ: PODD), best known for its Omnipod insulin delivery system, is emerging as a compelling ...
Investor's Business Daily on MSN
Insulet Rises As Broad Omnipod Growth Stokes Beat-And-Raise Quarter
Insulet stock rose moderately early Thursday as its insulin pump, Omnipod, delivered double-digit growth in the U.S. and ...
Q3 2025 Management View CEO Ashley McEvoy welcomed Flavia Pease as the new CFO and announced Eric Benjamin's promotion to COO and the appointment of Manoj Raghunandanan as Chief Growth Officer. McEvoy ...
Insulet reported Omnipod revenue of $699.2 million for the third quarter of 2025, up 31% over the same quarter in 2024 ...
Following the strong performance, Insulet raised its full-year 2025 revenue growth guidance to 28-29% in constant currency, up from its previous outlook of 24-27%. The company also increased its gross ...
11d
Insulet (PODD): Evaluating Valuation After Q3 2025 Results, Upgraded Guidance, and Omnipod Expansion
Insulet (PODD) delivered third-quarter 2025 results that surpassed analyst predictions for both revenue and earnings. This outcome was due to meaningful expansion in its Omnipod insulin delivery ...
Insulet Corporation recently reported strong third quarter results, with revenue and earnings surpassing analyst expectations and the company raising its full-year revenue and margin guidance. Key ...
Insulet’s recent earnings call paints a picture of robust performance and strategic growth, marked by record revenue achievements and significant market expansion. The sentiment was overwhelmingly ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback